Foghorn Therapeutics Provides Corporate Update

NEXT STORY
Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
PREV STORY
Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Affimed Provides Update on NK-Cell Immuno-Oncology Platform

Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly ...

author_avatar
NASDAQ Market News

Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor

NEW YORK, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress ...

author_avatar
NASDAQ Market News

Arizona Community Physicians Modernizes Infrastructure, Speeds Applications to Improve Patient Care with NetApp

SUNNYVALE, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- NetApp (NASDAQ:NTAP), empowering its customers to ...

author_avatar
NASDAQ Market News